The Canadian Cancer Trials Group (CCTG) is an academic cooperative oncology group that designs and conducts clinical trials testing cancer therapy, supportive care and prevention interventions across Canada.
The Canadian Cancer Trials Group
Applications are now open for the #CCTG 2026 New Investigator Training course (NITC)! This 2.5-day program equips Canadas next generation of cancer clinical trial investigators with the knowledge and skills needed to lead impactful research.
#CancerResearch #ClinicalTrials
buff.ly/Ij9U38k
#CCTG at #ASCO2026 our Senior Investigator Dr Jonathan Loree is the discussant at the GI oral abstract session.
A new #myeloMATCH clinical trial, #CCTG ALC10 has opened in Canada! Exploring a new treatment option for older adults with acute myeloid leukemia #AML who may not be able to tolerate intensive chemotherapy.
buff.ly/ABTpHbj
#Hematology #ClinicalTrials #BCCancer @swog.org
#CCTG HN.9 results presented at #ASCO26, highlighting the challenges of reducing treatment intensity while maintaining outcomes for patients with HPV-positive oropharyngeal cancer-investigating whether replacing the standard chemotherapy with immunotherapy could reduce side effects. buff.ly/bj30GIR
The #CCTG PR.21 secondary analysis presented at #ASCO26 explores treatment sequencing in advanced prostate cancer. Results support both therapies as treatment options and may help clinicians make more personalized treatment decisions based on patient preferences. buff.ly/DQLTfTB
Landmark CO.21 CHALLENGE #ASCO26 economic analysis shows that exercise programs can reduce health system costs. Dr Chen leading #CCTG researchers showed that structured exercise has positive outcomes for patients and at a lower cost than most treatment regimens. buff.ly/xQTzQVY
A simple blood test may detect tumor relapse in patients with early-stage germ cell tumors. The interim results of the @swog.org S1823 (#CCTG GCC1) study presented at #ASCO26 could identify patients at higher risk of relapse earlier Presented by #DrLuciaNappi buff.ly/wLDl01S @vchresearch.bsky.social
A simple blood test may detect tumor relapse in patients with early-stage germ cell tumors. The interim results of the @swog.org S1823 (#CCTG GCC1) study presented at #ASCO26 could identify patients at higher risk of relapse earlier Presented by #DrLuciaNappi buff.ly/wLDl01S @vchresearch.bsky.social
This $3,000 supervised exercise program drastically cuts colon cancer recurrence. Here’s why Canadian doctors say it should be prescribed and funded like a drug, by Megan Ogilvie www.thestar.com/news/canada/... via @thestar.com
A groundbreaking study led by VCHRI researcher Dr. Lucia Nappi identified a blood biomarker that could help doctors predict the early-stage germ cell cancer relapse & begin active treatment sooner: buff.ly/wLDl01S @cctg.bsky.social
The Canadian Cancer Trials Group
The Canadian Cancer Trials Group
The Canadian Cancer Trials Group
The Canadian Cancer Trials Group
The interim results of the GCC.1 / S1823 study were presented at ASCO 2026 during the Genitourinary Cancer Session. The study focuses on patients with early-stage germ cell tumors and the blood…
Supervised exercise programs, which cost about $3,000 per patient over three years, boost survival rates and save the health system money, study shows.
